Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

• Status: Withdrawn
• Trial end date: 2022-03-01

Summary

Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy

• Phase: Phase 2

Details

• Lead Sponsor: Costantine Albany
• Collaborator: Tesaro, Inc.
• Treatments: 8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one; BB 1101; Cisplatin; Dexamethasone; Dexamethasone acetate; Olanzapine; Palonosetron; Rolapitant